Mukdahan International Hospital Public Company (HANN) Fair Value & Analysis
Healthcare · TH · Market cap 493M THB
Fair value as of: Jul 16, 2026
From 22 valuation models · updated 25 days ago
Fair value updated Jul 16, 2026, revised from 0.7800 THB to 0.6700 THB (−14.1%) since Jun 24, 2026. Share price −3.4% over the past month.
A solid business, but screening 21% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (0.8300 THB). The favourable scenario is already priced in.
- Solid but not exceptional quality (61/100) and above fair value, neither a clear bargain nor a standout compounder.
Price vs Fair Value (8 months)
White line = price, green steps = our fair value per fiscal year. As of Jul 16, 2026.
How to read this chart
8‑month range 0.8400 THB – 1.16 THB · fair‑value band 0.5000 THB – 0.8300 THB · the 0.8500 THB price screens above the 0.6700 THB fair value. As of Jul 16, 2026.
Analysis
Mukdahan International Hospital Public Company (HANN) currently trades at 0.8500 THB, while our model-based Fair Value estimate is 0.6700 THB, implying the stock looks roughly 21.2% overvalued today. The Quality Score stands at 61/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: medium).
Over the trailing twelve months, Mukdahan International Hospital Public Company generated revenue of 452M THB at a net margin of 0.8%. Revenue declined 9.3% year over year. It earns a return on equity of 1.5%. Net debt stands at 50.8M THB. Fundamentals as of Jul 16, 2026
Our scenario range runs from 0.5000 THB (bear case) to 0.8300 THB (bull case); at 0.8500 THB, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 30% below its 52-week high and 2% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at 11% fair-value upside, at -21%, HANN screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 22 models by family
Widest divergence: DCF Models (0.9000 THB) versus Earnings-Based (0.3300 THB). Highest evidence: Growth DCF (80).
Notify me when HANN reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 16, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 63 · Market factors (momentum, volatility) 36
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Mukdahan International Hospital Public Company Limited operates hospitals in Thailand. The company operates Mukdahan International Hospital, Ruampat Yasothon Hospital, and Dr. Han Hospital.
Full company description
Mukdahan International Hospital Public Company Limited operates hospitals in Thailand. The company operates Mukdahan International Hospital, Ruampat Yasothon Hospital, and Dr. Han Hospital. Its clinics and treatment centers include a physical therapy center, obstetrics and gynecology clinic, urology, pediatric clinic, accident and emergency center, family medicine clinic, general practice clinic, heart specialist clinic, and kidney center. The company also offers medical technology products, such as high-power laser therapy device; peripheral magnetic stimulation; and Fisioline Radiant, a radio frequency therapy device. In addition, it provides health checkup packages and programs comprising influenza vaccine, shingles vaccine, AVF/AVG prepaid package, hepatitis B vaccine package, Baby Love vaccine packages II and III, dengue vaccine package, endoscopy package, and pre-pregnancy health checkup program, as well as vaccine package to prevent hand, foot, and mouth disease. Further, the company is involved in hospital room sales; and medicine and medical supplies sales. Mukdahan International Hospital Public Company Limited was incorporated in 1995 and is headquartered in Mukdahan, Thailand.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2023 – FY2025 · reported fiscal years
Mukdahan International Hospital Public Company reported revenue of 463M THB in FY2025 versus 527M THB in FY2023, a compound −6.3%/yr. Reported net income was 22.0M THB in FY2025, compounding −11.1%/yr from FY2023.
HANN screens 21% overvalued. Compare with HCA Healthcare, Inc →
Peer Group
Medical Care Facilities · 261 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Care Facilities median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Jul 16, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| HCA Healthcare, Inc HCA | $378.85 | $554.93 | +46% |
| Fresenius SE FRE | €41.73 | €32.15 | -23% |
| Dr. Sulaiman Al Habib Medical Services Group 4013 | 235.00 SAR | 112.37 SAR | -52% |
| IHH Healthcare Berhad, an investment holding company, Q0F | 2.58 SGD | 1.44 SGD | -44% |
| Tenet Healthcare Corporation THC | $194.91 | $338.05 | +73% |
| Rede D'Or São Luiz S.A RDOR3 | R$36.01 | R$47.31 | +31% |
| DaVita Inc DVA | $231.61 | $255.97 | +11% |
| Apollo Hospitals Enterprise Limited APOLLOHOSP | ₹8,955 | ₹2,955 | -67% |
| Fresenius Medical Care AG FMS | $24.68 | $45.60 | +85% |
| Aier Eye Hospital Group 300015 | ¥8.68 | ¥7.67 | -12% |
Compare Mukdahan International Hospital Public Company with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Mukdahan International Hospital Public Company (HANN) overvalued or undervalued?
What is the fair value of HANN?
What is the quality score of HANN?
What is the revenue of Mukdahan International Hospital Public Company (HANN)?
What is the net profit margin of HANN?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Mukdahan International Hospital Public Company and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.